Skip to main content
. Author manuscript; available in PMC: 2019 Dec 31.
Published in final edited form as: Am J Gastroenterol. 2010 Feb 9;105(5):1133–1139. doi: 10.1038/ajg.2010.9

Table 6.

Clinical outcomes of patients with detectable human anti-chimeric antibodies or subtherapeutic infliximab concentrations

Response to test Complete/partial response (%) P value
Detectable HACA Increase infliximab 1/6 (17) P < 0.004
Change anti-TNF 11/12 (92)
Subtherapeutic concentration Increase infliximab 25/29 (86) P < 0.016
Change anti-TNF 2/6 (33)

HACA, human anti-chimeric antibody; TNF, tumor necrosis factor.